Looking Into Ascendis Pharma's Recent Short Interest

Ascendis Pharma's (NYSE:ASND) short percent of float has risen 13.75% since its last report. The company recently reported that it has 3.35 million shares sold short, which is 8.52% of all regular sha

BenzingaApr 26 11:30 ET

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%

European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.5% to 1,380.32 on the S&P Europe Select ADR Index. With the gain, the index is set to c

MT NewswiresApr 26 11:09 ET

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

COPENHAGEN, Denmark, April 25, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will report first quarter 2024 financial results and provide a business update on Thursday, May 2, 2024,

GlobeNewswireApr 25 16:46 ET

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading

European equities traded in the US as American depositary receipts were trending modestly higher Thursday morning, rising 0.24% to 1,364.10 on the S&P Europe Select ADR Index. From continental Europe,

MT NewswiresApr 25 11:06 ET

Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism

Ascendis Pharma (ASND) said Wednesday that the UK's Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for Yorvipath as a parathyroid hormone, or PTH, replacement

MT NewswiresApr 24 11:33 ET

Express News | MHRA Approves YORVIPATH In Great Britain For Adults With Chronic Hypoparathyroidism

Moomoo 24/7Apr 24 08:31 ET